OncoMark has developed a novel prognostic test for breast cancer that identifies those patients who do not require chemotherapy, a market worth €1.1BN.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free